{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-004045","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.795941+00:00","generated_at":"2026-05-28T05:49:07.827858+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rapport reports positive Phase 1 RAP-219 data; CMO steps down","bullets":["PET trial: dosing regimen used in Phase 2a epilepsy trial exceeded target receptor occupancy (50-70%) within 5 days.","MAD-2 trial: no sedation or motoric impairment observed; all adverse events Grade 1 or 2.","Phase 2a focal epilepsy trial on track; topline data expected mid-2025.","Bradley Galer, M.D., stepped down as Chief Medical Officer; search for successor underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-004045","json":"https://secwatch.observer/filing/0001193125-25-004045.json","markdown":"https://secwatch.observer/filing/0001193125-25-004045.md","text":"https://secwatch.observer/filing/0001193125-25-004045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525004045/0001193125-25-004045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525004045/d925938d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:49:07.827858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}